ESPERION. REACHING GOALS Q4 and FY 2023 Earnings Presentation February 27, 2024 Forward-looking Statements & Disclosures This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.42 per share when it actually produced a loss of $0.37, delivering a surprise of 11.90%.Over the last four quarters, t ...

\ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1870780 (State or Other Juris ...

Esperion Therapeutics (ESPR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. Already registered? Access with your PIN here.  A ...

CONCORD, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous accompanying campaigns and initiatives, all driving awareness of its two brands – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid) used for adults on a statin to reduce LDL-cholesterol. Esperion's season debut comes in the first race at Richmond this spring (March 31) on the No. 17 of Chris Buesc ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Alexis Callahan - Head of Investor Relations Sheldon Koenig - President & Chief Executive Officer Ben Halladay - Chief Financial Officer JoAnne Foody - Chief Medical Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Tom Shrader - BTIG Troy Langford - TD Cowen Jason Zemansky - Bank of America Serge Belanger - Needham Operator Ladies and ...

• On max tolerated statin Important Safety Information | --- | --- | |-------------------------------------|----------------------| | FY 2023 R&D Guidance | $100 - 110 Million | | FY 2023 SG&A Guidance | $125 - 135 Million | | FY 2023 Op Ex Guidance1 | $225 - 245 Million | | Q3 2023 Common Shares Outstanding 2 | 112.1 Million | © 2023 Esperion. All/Rights Reserved – Do not copy or distribute. 13 © 2023 Esperion. All Rights Reserved – Do not copy or distribute. Corporate Update • Filed Rule 12(c) motion, req ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1870780 (State or other jurisdict ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Alexis Callahan - Head of Investor Relations Sheldon Koenig - President and Chief Executive Officer Eric Warren - Chief Commercial Officer Benjamin Halladay - Chief Financial Officer JoAnne Foody - Chief Medical Officer Betty Swartz - Chief Strategy Officer Conference Call Participants Dennis Ding - Jefferies Serge Belanger - Needham & Company Joseph Thome - Cowen Thomas Shrader - BTIG J ...